Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration (FDA) raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. The FDA's written response to the company's Type C meeting request provides a clearer regulatory path forward, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population. Emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The HARMONIC trial is a randomized, double-blind, placebo-controlled study assessing LP-300 in combination with standard chemotherapy versus chemotherapy alone. The amendments aim to refine the patient population to those most likely to benefit, potentially increasing the trial's efficiency and likelihood of success. This regulatory milestone is significant because it addresses an unmet medical need: never-smokers with NSCLC often have distinct tumor biology and limited treatment options after targeted therapy failure.
Lantern Pharma is a clinical-stage precision oncology company leveraging its proprietary RADR platform, which uses artificial intelligence and machine learning to streamline drug development. The company's pipeline includes LP-184 and LP-284 for various solid and hematologic tumors, and LP-300 for NSCLC. Through its subsidiary Starlight Therapeutics, Lantern is also developing LP-184 for pediatric CNS cancers.
The company's AI co-scientist platform, withZeta.ai, is now commercially available as a subscription-based research platform, representing a new revenue stream. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
For more details, visit the full press release at https://ibn.fm/Rxklm and the company's newsroom at https://ibn.fm/LTRN.
